Page last updated: 2024-12-05
captodiamine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
captodiamine: Captodiamine represents an interesting strategy for achieving benzodiazepine substitution with a low risk of dependence or impairment of cognitive function [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10240 |
| CHEMBL ID | 2110809 |
| CHEBI ID | 135521 |
| SCHEMBL ID | 466131 |
| MeSH ID | M0479846 |
Synonyms (61)
| Synonym |
|---|
| ethanamine, 2-[[[4-(butylthio)phenyl]phenylmethyl]thio]-n,n-dimethyl- |
| captodiamine |
| vufb2350 |
| captodiamin |
| brn 2625367 |
| n 68 |
| einecs 207-629-1 |
| captodramin |
| p-butylmercaptobenzhydryl-beta-dimethylamino-ethylsulphide |
| captodiame |
| covatix |
| 2-((p-(butylthio)-alpha-phenylbenzyl)thio)-n,n-dimethylethylamine |
| captodiamo [inn-spanish] |
| captodiamum [inn-latin] |
| ethanamine, 2-(((4-(butylthio)phenyl)phenylmethyl)thio)-n,n-dimethyl- |
| ethylamine, 2-((p-(butylthio)-alpha-phenylbenzyl)thio)-n,n-dimethyl- |
| kaptodiamin [czech] |
| captodramine |
| captodiame [inn:ban] |
| covatin |
| captodiame (ban) |
| 486-17-9 |
| D07316 |
| CHEBI:135521 |
| 2-[(4-butylsulfanylphenyl)-phenylmethyl]sulfanyl-n,n-dimethylethanamine |
| kaptodiamin |
| captodiamo |
| unii-h93k9455dd |
| captodiamum |
| 4-06-00-06672 (beilstein handbook reference) |
| h93k9455dd , |
| captodiame [inn] |
| p-butylthiodiphenylmethyl 2-dimethylaminoethyl sulfide |
| ethylamine, 2-((p-(butylthio)-.alpha.-phenylbenzyl)thio)-n,n-dimethyl- |
| 2-(p-(butylthio)-.alpha.-phenylbenzylthio)-n,n-dimethylethylamine |
| captodiame [who-dd] |
| p-butylthiodiphenylmethyl 2-dimethylaminoethyl sulphide |
| captodiamine [mi] |
| butylthiodiphenylmethyl 2-dimethylaminoethyl sulfide |
| 2-((p-(butylthio)-.alpha.-phenylbenzyl)thio)-n,n-dimethylethylamine |
| n-(2-([[4-(butylsulfanyl)phenyl](phenyl)methyl]sulfanyl)ethyl)-n,n-dimethylamine # |
| IZLPZXSZLLELBJ-UHFFFAOYSA-N |
| ethylamine, 2-[[p-(butylthio)-.alpha.-phenylbenzyl]thio]-n,n-dimethyl- |
| p-butylthiodiphenylmethyl 2-(dimethylamino)ethyl sulfide |
| captodiam |
| p-butylmercaptobenzhydryl .beta.-dimethylaminoethyl sulfide |
| vufb 2350 |
| suvren (salt/mix) |
| p-butylmercaptobenzhydryl-.beta.-dimethylamino-ethylsulphide |
| SCHEMBL466131 |
| CHEMBL2110809 |
| 2-[(4-butylsulfanylphenyl)-phenyl-methyl]sulfanyl-n,n-dimethylethanamine |
| DB09014 |
| n-(2-{[[4-(butylsulfanyl)phenyl](phenyl)methyl]sulfanyl}ethyl)-n,n-dimethylamine |
| Q2937681 |
| 7-nitro-1,2,3,4-tetrahydro-isoquinoline hcl |
| DTXSID50862014 |
| captodiamin; captodiamine; captodramin; captodramine; covatin |
| ethanamine, 2-(((4-(butylthio)phenyl)phenylmethyl)thio)-n,n-dimethyl- (9ci) |
| STARBLD0009544 |
| AKOS040745647 |
Research Excerpts
Effects
| Excerpt | Reference | Relevance |
|---|---|---|
| "Captodiamine has also been found to ameliorate stress-induced anhedonia, reduce the associated elevations of hypothalamic corticotrophin-releasing factor (CRF) and restore the reductions in hypothalamic BDNF expression." | ( Captodiamine, a putative antidepressant, enhances hypothalamic BDNF expression in vivo by synergistic 5-HT2c receptor antagonism and sigma-1 receptor agonism. Regan, CM; Ring, RM, 2013) | 2.55 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| diarylmethane | Any compound containing two aryl groups connected by a single C atom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (17)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 13 (76.47) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 27.65
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.65) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (5.88%) | 5.53% |
| Reviews | 1 (5.88%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (88.24%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||